|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Abbreviations ADME absorption distribution metabolism excretion HTVS highthroughput virtual screening MD molecular dynamics MMGBSA molecular mechanics generalized bonn solvation accessible PDB protein data bank PPAR peroxisome proliferator-activated receptor RMSD Root mean square deviation RMSF Root mean square fluctuation SAR structural activity relationship SP simple precision T2DM TypeII diabetes mellitus XP Extra precision Communicated by Ramaswamy H. Sarma.
|
30767625 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Chronic oleoylethanolamide treatment attenuates diabetes-induced mice encephalopathy by triggering peroxisome proliferator-activated receptor alpha in the hippocampus.
|
31299417 |
2019 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Previously, we showed that Krüppel-like factor (KLF)-5 regulates cardiomyocyte PPARα and fatty acid oxidation-related gene expression in diabetes.
|
31029826 |
2019 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Activation of PPARα by fenofibrate normalized ECFC/CAC numbers and mitochondrial function in diabetes.
|
31451517 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Synthetic PPAR ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists) while a new generation of dual agonists reveals hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action.
|
31161987 |
2019 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The expression of PPAR-α can be used as a new basis for the diagnosis and treatment of NAFLD complicated with DM.
|
29434731 |
2018 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
AA, LXA4 and EETs regulate smooth muscle function and proliferation, voltage gated ion channels, cell membrane fluidity, membrane receptors, G-coupled receptors, PPARs, free radical generation, nitric oxide formation, inflammation, and immune responses that, in turn, participate in the regulation blood pressure and pathogenesis of diabetes mellitus.
|
30034875 |
2018 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The abnormal expression of PPAR-α is closely related to atherosclerosis, indicating that the correlation between PPAR-α methylation levels in peripheral blood and atherosclerosis of NAFLD patients with DM can provide a new direction of diagnosis and treatment.
|
29456675 |
2018 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Down-regulation of PPARs genes in the pancreas of diabetic rats after treatment with okra, demonstrates that okra may improve glucose homeostasis and β-cells impairment in diabetes through a PPAR-dependent mechanism.
|
29308616 |
2018 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
However, the mechanism for diabetes-induced downregulation of PPARα remains unknown.
|
28270521 |
2017 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The gradual impairment of insulin production and signalling in diabetes is associated with elevated plasma fatty acids and increased myocardial free fatty acid uptake and activation of the transcription factor PPARα.
|
28177068 |
2017 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Taken together, these findings indicate that IGFBP-2 might be a new target of metformin action in diabetes and the metformin-AMPK-Sirt1-PPARα-IGFBP-2 network may provide a novel pathway that could be applied to ameliorate metabolic syndromes by controlling IGF-1 bioavailability.
|
27009398 |
2016 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
A more renal prominent activation of Wnt signaling was detected both in PPARα<sup>-/-</sup> mice with diabetes or obstructive nephropathy and in PPARα<sup>-/-</sup> tubular cells treated with Wnt3a.
|
27543085 |
2016 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients.
|
24921414 |
2014 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
|
23603006 |
2013 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes.
|
23583468 |
2013 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
On the other hand, no interaction between diabetes and PPAR +294T/C polymorphism on the risk of ischemic stroke was found (p = 0.089).
|
23512374 |
2013 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.
|
23147557 |
2013 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
|
24113216 |
2013 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The purpose of the present study was to identify the association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with diabetes, insulinaemia and insulin resistance.
|
20420754 |
2010 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
However, PPARA genotype correlated with 5-year mortality in diabetic (22.2% AA vs. 18.8% AG vs. 39.5% GG; P = 0.008), but not non-diabetic (P = 0.96) subjects (genotype by diabetes interaction P = 0.008).
|
20838448 |
2010 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Importantly, synthetic PPARalpha and PPARgamma ligands are currently used for treating hyperlipidemia and diabetes.
|
19866471 |
2010 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Studies on the association of the Pro12Ala and C1431T polymorphisms of PPAR? with diabetes and obesity have revealed extensive population-dependent variations.
|
19805902 |
2009 |
|
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
While candidate gene approaches have not been tremendously successful in identifying relevant genetic contributors to obesity, except PPAR , the advent of genome-wide strategies has recently revealed novel and unexpected genetic factors with strong associations with obesity and/or diabetes, i.e.
|
18230892 |
2008 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Synthetic PPAR agonists, such as fibrates and thiazolidinediones are already used to treat hyperlipidemia and diabetes mellitus, respectively.
|
18191967 |
2008 |